Weekly Roundup: Patents, presentations and preclinical data
Riding the wave of BioEquity, it has been another busy week for Optimum’s clients. Hansa Biopharma, Poolbeg Pharma and Resolution Therapeutics are all taking to the stage across Europe and the US. Optimum’s own Stephen Adams will be chairing a panel at LSX Nordic next week after yet another fascinating Hot Topic – this time on how our advancing knowledge of obesity might help us better treat eating disorders like anorexia.
Hansa Biopharma participating at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
Hansa Biopharma AB, announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat at H.C. Wainwright’s 4th Annual BioConnect Investor Conference at Nasdaq in New York, from 17:00-17:30 EDT on Tuesday 19 May, 2026.
Poolbeg Pharma plc announced patent granted in Canada for POLB 001 and data will be presented in a poster presentation at EHA 2026 Congress
Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announced that it has received formal notification of the grant of its patent application from the Canadian patent office for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome.
The Company also announced that it will present data on POLB 001 at the European Hematology Association Congress, taking place 11-14 June 2026 in Stockholm.
Resolution Therapeutics showcased key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026
Resolution Therapeutics Limited, a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, presented key preclinical data on its Regenerative Macrophage Therapy RTX001 in an oral presentation at the ASGCT Annual Meeting in Boston.
AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer
AstronauTx Ltd, a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, announced the appointments of Dr. Michelle Mellion as Chief Medical Officer (CMO) and Deb Gouveia as Vice President, Clinical Operations and Development Strategy.
ViCentra announced the commercial launch of Kaleido, a new smartphone-controlled automated insulin delivery patch pump system
ViCentra, a European medical device company commercialising the Kaleido insulin patch pump system, launched its new smartphone-controlled hybrid closed loop system, with first commercial deliveries in Germany and the Netherlands planned for later this summer.
📢 Hot topic
Watch this week’s Hot Topic, discussing the potential to utilise the knowledge we’ve gained developing anti-obesity drugs to better treat anorexia nervosa.
Eating disorders, such as anorexia nervosa, are more common than people think, with an estimated 1.25m people in the UK alone suffering from them, according to the British charity Beat Eating Disorders. But could the science that’s helped us develop anti-obesity treatments like GLP-1s actually assist those struggling with anorexia by improving their appetite and helping them put on weight?
Watch our latest Hot Topic with Optimum’s Stephen Adams here ⬇️
For more of a deep dive, listen to Dr Amanda Banks MD’s podcast interview with the New England Journal of Medicine.
https://www.nejm.org/do/10.1056/NEJMdo008508/full/
👥Industry events
LSX Nordic Congress – Copenhagen | 19-20th May 2026
From formal partnering sessions to spontaneous coffee station conversations, this is where authentic, face-to-face connections happen. Whether you’re an innovator, investor, or strategic partner, the LSX Nordic Congress is your gateway to meaningful collaborations.
Optimum’s own Stephen Adams will be chairing the opening panel at 8.40am on Tuesday 19th – Nordic Horizons: Maximising Growth, Investment and Internationalisation in The Nordic Life Sciences Ecosystem – and will be around all day, so drop him an email at stephen@optimumcomms.com if you’d like to meet up.
On Helix – Cambridge | 9th Jul 2026
Just two months until One Nucleus presents ON Helix – Disrupting Bio Innovation.
A one-day conference in Cambridge spotlighting and discussing the breakthrough technologies, policies and business models that are shaping the drug discovery and development landscape.
An excellent opportunity to connect with the pioneers leading this next wave of disruptive innovation and ensure you stay ahead in a rapidly evolving space.
Optimum is a proud supporter of One Nucleus events and is happy to share an exclusive 10% F&F discount. Please get in touch if you would like to use this or connect with the team there!
Optimum’s 18th Annual Healthcare Investor Conference – London | 8th Oct 2026
Save the date – Thursday the 8th of October 2026!
The date is set for Optimum’s 18th Annual Healthcare Investor Conference, which returns to the King’s Fund, London this October.
Join us for a day of invaluable insights from the thought leaders of the life sciences industry! The conference is free but invitation only, so please register your interest to attend here: https://www.optimumcomms.com/irconference2026/
Follow us on LinkedIn to hear updates on speakers and panellists, as they are announced.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
